Clinical Trial Detail

NCT ID NCT03178851
Title Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

melanoma

Therapies

Atezolizumab

Atezolizumab + Cobimetinib

Age Groups: senior adult

Additional content available in CKB BOOST